Ensysce Biosciences Operating Profit Margin Over Time
| ENSC Stock | USD 0.43 0.16 27.12% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Ensysce Biosciences Performance and Ensysce Biosciences Correlation. Ensysce |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ensysce Biosciences. If investors know Ensysce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ensysce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.94) | Revenue Per Share 0.274 | Quarterly Revenue Growth (0.63) | Return On Assets (1.32) | Return On Equity (4.28) |
The market value of Ensysce Biosciences is measured differently than its book value, which is the value of Ensysce that is recorded on the company's balance sheet. Investors also form their own opinion of Ensysce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ensysce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ensysce Biosciences' market value can be influenced by many factors that don't directly affect Ensysce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ensysce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ensysce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ensysce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Operating Profit Margin Analysis
Compare Ensysce Biosciences and related stocks such as Zura Bio Limited, Phio Pharmaceuticals Corp, and Sonnet Biotherapeutics Operating Profit Margin Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZURA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| PHIO | (134) | (134) | (134) | (52.5038) | (124) | (301) | (474) | (937) | (53.3623) | (428) | (428) | (428) | (428) | (492) | (517) |
| SONN | (0.1159) | (0.1159) | (0.1159) | (0.3313) | (0.1159) | (0.271) | (0.0628) | (0.0608) | (0.0999) | (51.8736) | (51.8736) | (84.7834) | (127) | (0.0999) | (0.1) |
| ATNF | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| CDIO | (689) | (689) | (689) | (689) | (689) | (689) | (689) | (689) | (689) | (689) | (689) | (689) | (4.8 K) | (424) | (446) |
| VRAX | (6.5205) | (6.5205) | (6.5205) | (6.5205) | (6.5205) | (6.5205) | (6.5205) | (6.5205) | (6.5205) | (6.5205) | (5.2055) | (670) | (670) | (41.5325) | (43.61) |
| REVB | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| KPRX | (19.9427) | (19.9427) | (19.9427) | (19.9427) | (19.9427) | (19.9427) | (19.9427) | (35.7266) | (6.5625) | (2.6065) | (679) | (679) | (679) | (781) | (742) |
| QNRX | (54.7036) | (54.7036) | (54.7036) | (54.7036) | (54.7036) | (54.7036) | (54.7036) | (54.7036) | (54.7036) | (54.7036) | (54.7036) | (54.7036) | (54.7036) | (49.23) | (51.69) |
| ALLR | (147) | (147) | (147) | (147) | (147) | (147) | (147) | (147) | (147) | (147) | (147) | (147) | (147) | (132) | (139) |
| BDRX | (30.6054) | (30.6054) | (30.6054) | (30.6054) | (49.1401) | (7.3396) | (7.2955) | (11.907) | (6.0965) | (16.7923) | (31.1108) | (12.1073) | (12.7783) | (21.0341) | (22.09) |
Ensysce Biosciences and related stocks such as Zura Bio Limited, Phio Pharmaceuticals Corp, and Sonnet Biotherapeutics Operating Profit Margin description
My Equities
My Current Equities and Potential Positions
| Ensysce Biosciences | ENSC |
| Classification | Pharmaceutical Products |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.43
Check out Ensysce Biosciences Performance and Ensysce Biosciences Correlation. For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Ensysce Biosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.